Fig. 7.

Glioblastoma successfully treated by MP-MUS in an intracranial xenograft model.

(A) Kaplan–Meier plot of mice after intracranial injection following 3 × Saline or 3 × MP-MUS (8 mg/kg) tail vein injections, n = 11.

(B) Alteration in mouse body mass during course of trial shows that MP-MUS treated gain and hold body weight better than saline treated.

(C) Labeling of uninjected hemisphere of saline treated mouse with (I) anti-vimentin (human glioblastoma cells) IgG, (III) CD3-ε (mouse immune cells) and (II) no-primary IgG control (background peroxidase activity).

(D) Images of C. (I) taken as increasing magnification demonstrating the pattern of infiltration of the brain by the glioblastoma cells.

(E) Unambiguous demonstration that vimentin labeling co-localized with DAPI/nuclear DNA can be seen by attenuation of fluorescent nuclei within glioblastoma DAB staining.

(F) Levels of glioma and CD3-ε in MP-MUS treated brain (right hemispheres).

MP-MUS #1 displays vimentin in human glioblastoma, found only on a single slide, but CD3-ε labeling is found throughout hemisphere.

MP-MUS #8 has the most vimentin signal, hence glioblastoma cells, of any of the MP-MUS treated mice.